Then you’ve got Sanofi-Aventis . The firm’s new CEO just laid out a fresh growth strategy targeting small to medium-sized acquisitions in vaccines, generics and over-the-counter drugs.
And then there’s Roche , which launched a hostile offer on Monday to acquire, directly from stockholders, the 44 percent of biotechnology company Genentech it does not already own for $86.50 a share.
What’s the trade, now?
I’d look at Amgen , says Guy Adami. I don’t think they’re a takeover target but they’re a good company.
And put Johnson & Johnson on your radar too, adds Tim Seymour.
Got something to to say? Send us an e-mail at email@example.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to firstname.lastname@example.org.
Trader disclosure: On Feb. 11th, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Najarian Owns (CAT) Call Spread, (ENER) Call Spread, (EEM) Call Spread, (GDX) Call Spread, (GLD) Call Spread, (STI) Call Spread, (MOS) Call Spread; Najarian Owns (CHK) Put Spread; Najarian Owns (FCX) & (FCX) Calls; Najarian Owns (GS) Calls; Najarian Owns (GE) Puts; Najarian Owns (MSFT) & (MSFT) Short Calls; Najarian Owns (MS) & (MS) Short Calls; Terranova Owns (DIS), (KCE), (XBI), (FXC); Terranova Owns (IBM) Call Spread; Terranova Owns (AMGN) Puts; Seymour Owns (MT), (BAC), (EEM), (FXI); Seymour's Firm Owns (VIP), (TKC); Adami Owns (AGU), (BTU), (C), (GS), (INTC), (MSFT), (NUE)